1. Home
  2. MEOH vs PBLS Comparison

MEOH vs PBLS Comparison

Compare MEOH & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Methanex Corporation

MEOH

Methanex Corporation

N/A

Current Price

$71.21

Market Cap

3.7B

Sector

Industrials

ML Signal

N/A

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$28.03

Market Cap

3.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MEOH
PBLS
Founded
1968
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.5B
IPO Year
1995
2026

Fundamental Metrics

Financial Performance
Metric
MEOH
PBLS
Price
$71.21
$28.03
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
★ $72.50
$41.40
AVG Volume (30 Days)
480.4K
★ 1.1M
Earning Date
10-29-2026
11-17-2026
Dividend Yield
★ 1.18%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.29
N/A
Revenue Next Year
N/A
$300.17
P/E Ratio
$16.44
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.01
$22.66
52 Week High
$66.75
$42.49

Technical Indicators

Market Signals
Indicator
MEOH
PBLS
Relative Strength Index (RSI) 71.86 47.54
Support Level $58.11 $26.42
Resistance Level N/A $28.48
Average True Range (ATR) 2.40 2.42
MACD 0.38 0.59
Stochastic Oscillator 89.02 71.50

Price Performance

Historical Comparison
MEOH
PBLS

About MEOH Methanex Corporation

Methanex Corp operates as a producer and supplier of methanol to various international markets in North America, Asia Pacific, Europe and South America. The company's operations consist prominently of the production and sale of methanol, along with the production and sale of ammonia. Geographically, it operates in China, Europe, the United States, South America, South Korea, Other Asia, and Canada. The majority of revenue is derived from Europe.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: